Efficacy and safety of combination chemotherapy with docetaxel and cisplatin as a first-line treatment for advanced gastric cancer.
- Author:
Gyung Jung KIM
1
;
Sehe Dong LEE
;
Jong Won PARK
;
Cheol Ho SIN
;
Seung Jae HWANG
;
Seung Hyun NAM
;
Bong Seog KIM
Author Information
1. Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@e-bohun.or.kr
- Publication Type:Original Article
- Keywords:
Advanced castric cancer;
Docetaxel;
Cisplatin
- MeSH:
Adenocarcinoma;
Agranulocytosis;
Anemia;
Cisplatin*;
Disease Progression;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Infusions, Intravenous;
Male;
National Cancer Institute (U.S.);
Stomach Neoplasms*;
Thrombocytopenia
- From:Korean Journal of Medicine
2007;72(6):593-599
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUDN: To evaluate the activity and safety of docetaxel and cisplatin for advanced gastric cancer as a first-line chemotherapy treatment. METHODS: Between December 2001 and February 2006, forty-two patients with recurrent or metastatic gastric cancer were enrolled. Docetaxel (75 mg/m2) was administered as a 1-hour intravenous infusion on day 1 and cisplatin (60 mg/m2) was also administered as a 30-minute intravenous infusion on day 1 every three weeks until disease progression or severe toxicity was detected. The response was assessed every 2 cycles. The toxicities were evaluated for every course of chemotherapy according to NCI toxicity criteria. RESULTS: The median age of the patients was 66 (range, 33~77) years. Among the forty-two patients, 38 were male. Twenty-seven patients had an Eastern Cooperative Oncology Group performance score of 0 or 1 and fifteen patients had a score of 2. All patients had adenocarcinoma. Thirty-three of the forty-two patients were assessable for response. Partial responses were observed in 14 patients. The overall response rate was 42.4% (95% C.I., 25.259.6%) and the median response duration was 5.7 (range, 1.4~17.2) months. The median overall survival of all patients was 8.1 (range, 1.2~47.0) months. During a total of 170 cycles, granulocytopenia worse than National Cancer Institute toxicity grade 3 occurred in 7.6% of the patients, thrombocytopenia in 0.6% and anemia in 3.5%, respectively. No deaths resulting from toxicity were observed. Non-hematologic toxicities were minor and were easily controlled. CONCLUSION: Combination chemotherapy with docetaxel and cisplatin has a tolerable efficacy with acceptable toxicities in patients with advanced gastric cancer as a first-line treatment.
